US6018031A
(en)
*
|
1989-10-20 |
2000-01-25 |
Trustees Of Dartmouth College |
Binding agents specific for IgA receptor
|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
US20040258688A1
(en)
*
|
1995-01-31 |
2004-12-23 |
Daniel Hawiger |
Enhanced antigen delivery and modulation of the immune response therefrom
|
US20020187131A1
(en)
*
|
1995-01-31 |
2002-12-12 |
Daniel Hawiger |
Enhanced antigen delivery and modulation of the immune response therefrom
|
US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
US7371376B1
(en)
*
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
HUP0100929A3
(en)
*
|
1998-02-17 |
2005-10-28 |
Celldex Therapeutics Inc |
Treating and diagnosing macrophage-mediated diseases using fc receptor ligands
|
EP2275540B1
(de)
*
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Verfahren zur Steuerung der Aktivität von immunologisch funktionellen Molekülen
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
DK2283866T3
(en)
|
1999-06-25 |
2015-05-18 |
Genentech Inc |
METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
EP1189641B1
(de)
|
1999-06-25 |
2009-07-29 |
Genentech, Inc. |
Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
|
JP4579471B2
(ja)
*
|
1999-06-25 |
2010-11-10 |
ジェネンテック, インコーポレイテッド |
抗ErbB2抗体を用いる前立腺癌の処置
|
MXPA02000962A
(es)
*
|
1999-07-29 |
2002-07-02 |
Medarex Inc |
Anticuerpos monoclonales humanos para her2/neu.
|
ATE373017T1
(de)
*
|
1999-07-30 |
2007-09-15 |
Medarex Inc |
Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen
|
EP2829609A1
(de)
|
1999-08-24 |
2015-01-28 |
E. R. Squibb & Sons, L.L.C. |
Humane Antikörper gegen CTLA-4-Antikörper und Verwendungen davon
|
ES2330301T3
(es)
|
1999-08-27 |
2009-12-09 |
Genentech, Inc. |
Dosificaciones para tratamiento con anticuerpos anti-erbb2.
|
CA2385528C
(en)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
DE10006432A1
(de)
*
|
2000-02-14 |
2001-08-16 |
Ganzimmun Inst Fuer Ganzheitli |
Verfahren zum Nachweis von Helicobacter pylori in Stuhl- und Speichelproben
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
US20010051147A1
(en)
*
|
2000-03-27 |
2001-12-13 |
Van De Winkel Jan G.J. |
Methods for immunostimulation using binding agents for the Fc receptor of immunoglobulin A
|
ES2528794T3
(es)
|
2000-04-11 |
2015-02-12 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
AU2001259271A1
(en)
*
|
2000-04-28 |
2001-11-12 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
CA2408594A1
(en)
*
|
2000-05-08 |
2001-11-15 |
Medarex, Inc. |
Human monoclonal antibodies to dendritic cells
|
US7560534B2
(en)
*
|
2000-05-08 |
2009-07-14 |
Celldex Research Corporation |
Molecular conjugates comprising human monoclonal antibodies to dendritic cells
|
CN102698265A
(zh)
|
2000-05-19 |
2012-10-03 |
杰南技术公司 |
用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验
|
US20030138870A1
(en)
*
|
2000-06-27 |
2003-07-24 |
Megumi Tanaka |
Method of evaluating binding activity of ligand to lignad-binding protein
|
US6946292B2
(en)
*
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
ES2390425T3
(es)
|
2000-12-22 |
2012-11-12 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
NZ527977A
(en)
|
2001-02-12 |
2005-10-28 |
Medarex Inc |
Human monoclonal antibodies to FC alpha receptor (CD89)
|
US8163289B2
(en)
*
|
2001-03-09 |
2012-04-24 |
Iterative Therapeutics, Inc. |
Methods and compositions involving polymeric immunoglobulin fusion proteins
|
EP1395605B8
(de)
|
2001-03-09 |
2014-12-17 |
Iterative Therapeutics, Inc. |
Polymere immunoglobulin-fusionsproteine, die auf fc-gamma-rezeptoren mit geringer affinität zielen
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
EP1992643A3
(de)
|
2001-06-20 |
2008-12-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
WO2004058821A2
(en)
*
|
2002-12-27 |
2004-07-15 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
DE60237282D1
(de)
*
|
2001-06-28 |
2010-09-23 |
Domantis Ltd |
Doppelspezifischer ligand und dessen verwendung
|
US6997863B2
(en)
*
|
2001-07-25 |
2006-02-14 |
Triton Biosystems, Inc. |
Thermotherapy via targeted delivery of nanoscale magnetic particles
|
US7731648B2
(en)
*
|
2001-07-25 |
2010-06-08 |
Aduro Biotech |
Magnetic nanoscale particle compositions, and therapeutic methods related thereto
|
US7951061B2
(en)
*
|
2001-07-25 |
2011-05-31 |
Allan Foreman |
Devices for targeted delivery of thermotherapy, and methods related thereto
|
US7074175B2
(en)
|
2001-07-25 |
2006-07-11 |
Erik Schroeder Handy |
Thermotherapy via targeted delivery of nanoscale magnetic particles
|
WO2003024392A2
(en)
|
2001-09-18 |
2003-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US8323903B2
(en)
|
2001-10-12 |
2012-12-04 |
Life Technologies Corporation |
Antibody complexes and methods for immunolabeling
|
AU2002365258A1
(en)
*
|
2001-10-12 |
2003-09-02 |
University Of Vermont And State Agricultural College |
Binding peptides specific for the extracellular domain of erbb2 and uses therefor
|
US20050069962A1
(en)
*
|
2001-10-12 |
2005-03-31 |
Archer Robert M |
Antibody complexes and methods for immunolabeling
|
WO2003088808A2
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AU2002356844C1
(en)
*
|
2001-10-23 |
2010-03-04 |
Amgen Fremont Inc. |
PSMA antibodies and protein multimers
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
EP1575571A4
(de)
|
2002-01-02 |
2008-06-25 |
Genentech Inc |
Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
|
US7691568B2
(en)
|
2002-04-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Antibody composition-containing medicament
|
CA2481515C
(en)
|
2002-04-10 |
2013-10-01 |
Genentech, Inc. |
Anti-her2 antibody variants
|
US7799561B2
(en)
*
|
2002-06-12 |
2010-09-21 |
Sigma-Aldrich, Co. |
Affinity peptides and method for purification of recombinant proteins
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
PT1517921E
(pt)
*
|
2002-06-28 |
2006-09-29 |
Domantis Ltd |
Ligandos duplamente especificos com semi-vida no soro aumentada
|
PT1585966E
(pt)
|
2002-07-15 |
2012-02-20 |
Hoffmann La Roche |
Tratamento de cancro com o anticorpo anti-erbb2 rhumab 2c4
|
US20080260744A1
(en)
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
JP2006513702A
(ja)
*
|
2002-09-09 |
2006-04-27 |
ヌラ インコーポレーティッド |
Gタンパク質共役受容体およびその使用
|
EP1551876B1
(de)
|
2002-10-16 |
2011-03-16 |
Purdue Pharma L.P. |
Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
WO2004043375A2
(en)
*
|
2002-11-08 |
2004-05-27 |
Bristol-Myers Squibb Company |
Pharmaceutical compositions and methods of using taxane derivatives
|
WO2004048525A2
(en)
*
|
2002-11-21 |
2004-06-10 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
|
US20080014594A1
(en)
*
|
2003-01-31 |
2008-01-17 |
Kevin Hestir |
Lung-Expressed Polypeptides
|
CA2514979A1
(en)
*
|
2003-01-31 |
2004-09-02 |
Celldex Therapeutics, Inc. |
Antibody vaccine conjugates and uses therefor
|
US9259459B2
(en)
*
|
2003-01-31 |
2016-02-16 |
Celldex Therapeutics Inc. |
Antibody vaccine conjugates and uses therefor
|
US20040156846A1
(en)
*
|
2003-02-06 |
2004-08-12 |
Triton Biosystems, Inc. |
Therapy via targeted delivery of nanoscale particles using L6 antibodies
|
JP3803790B2
(ja)
*
|
2003-02-17 |
2006-08-02 |
株式会社東北テクノアーチ |
新規なダイアボディ型二重特異性抗体
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
SI1641822T1
(sl)
|
2003-07-08 |
2013-08-30 |
Genentech, Inc. |
IL-17 A/F heterologni polipeptidi in njihove terapevtske uporabe
|
WO2005048928A2
(en)
*
|
2003-11-12 |
2005-06-02 |
George Mason Intellectual Property |
Methods for treating viral infection
|
EP1689432B1
(de)
|
2003-11-17 |
2009-12-30 |
Genentech, Inc. |
Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
|
EP1570858A1
(de)
*
|
2004-03-05 |
2005-09-07 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Monovalenter Ligand des FcalphaRI-Rezeptors als ein antiinflammatorisches Agens
|
MXPA06011199A
(es)
|
2004-03-31 |
2007-04-16 |
Genentech Inc |
Anticuerpos anti-tgf-beta humanizados.
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
NZ551180A
(en)
|
2004-06-01 |
2009-10-30 |
Genentech Inc |
Antibody drug conjugates and methods
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US7964195B2
(en)
|
2005-01-07 |
2011-06-21 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
EP3698807A1
(de)
|
2005-01-21 |
2020-08-26 |
Genentech, Inc. |
Fixe dosierung von her-antikörpern
|
CA2595395A1
(en)
*
|
2005-02-09 |
2006-08-17 |
Genentech, Inc. |
Inhibiting her2 shedding with matrix metalloprotease antagonists
|
AU2006216732C1
(en)
*
|
2005-02-23 |
2017-07-20 |
Genentech, Inc. |
Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
|
WO2006096861A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
LT2439273T
(lt)
|
2005-05-09 |
2019-05-10 |
Ono Pharmaceutical Co., Ltd. |
Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
US7741053B2
(en)
*
|
2005-05-13 |
2010-06-22 |
Sigma-Aldrich Co. |
Processes for purification of recombinant proteins
|
US7858843B2
(en)
|
2005-06-06 |
2010-12-28 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
CN105330741B
(zh)
|
2005-07-01 |
2023-01-31 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
EP1922412A4
(de)
*
|
2005-07-15 |
2009-07-15 |
Siemens Healthcare Diagnostics |
Humanisierte antikörperkonjugate und entsprechende verfahren, tests, reagenzien und kits
|
DK1912675T3
(en)
|
2005-07-25 |
2014-03-24 |
Emergent Product Dev Seattle |
B-cell reduction using specific and cd37-cd20-specific binding molecules
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
US8906864B2
(en)
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
AU2006335053A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
US8052971B2
(en)
*
|
2005-11-21 |
2011-11-08 |
MG Biologics |
Oral use of specific antibodies for intestinal health
|
TW200730539A
(en)
*
|
2005-12-01 |
2007-08-16 |
Domantis Ltd |
Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
|
CA2638821A1
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
EP1996716B1
(de)
*
|
2006-03-20 |
2011-05-11 |
The Regents of the University of California |
Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
|
EP2614839A3
(de)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
|
US9044461B2
(en)
|
2006-04-07 |
2015-06-02 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
EP2010226B1
(de)
*
|
2006-04-07 |
2014-01-15 |
The Research Foundation of State University of New York |
Transcobalaminrezeptor-Polypeptide, -Nukleinsäuren und -Modulatoren sowie entsprechende Verfahren zur Verwendung für die Modulation von Zellwachstum und die Behandlung von Krebs und Cobalaminmangel
|
EP2082645A1
(de)
|
2006-04-19 |
2009-07-29 |
Genentech, Inc. |
Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
|
JP2009539413A
(ja)
*
|
2006-06-12 |
2009-11-19 |
トゥルビオン・ファーマシューティカルズ・インコーポレーテッド |
エフェクター機能を有する単鎖多価結合タンパク質
|
US8586006B2
(en)
|
2006-08-09 |
2013-11-19 |
Institute For Systems Biology |
Organ-specific proteins and methods of their use
|
MX2009005189A
(es)
|
2006-11-15 |
2009-06-30 |
Medarex Inc |
Anticuerpos humanos monoclonales para btla y metodos de uso.
|
JP5391073B2
(ja)
|
2006-11-27 |
2014-01-15 |
ディアデクサス インコーポレーテッド |
Ovr110抗体組成物および使用方法
|
WO2008109440A2
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
KR20100040840A
(ko)
*
|
2007-06-06 |
2010-04-21 |
도만티스 리미티드 |
폴리펩티드,항체 가변 도메인 및 길항제
|
US9551033B2
(en)
*
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
WO2008154249A2
(en)
*
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
CN101990439A
(zh)
*
|
2007-07-06 |
2011-03-23 |
特鲁比昂药品公司 |
具有置于c末端的特异性结合结构域的结合肽
|
JP5469600B2
(ja)
|
2007-07-16 |
2014-04-16 |
ジェネンテック, インコーポレイテッド |
抗CD79b抗体及びイムノコンジュゲートとその使用方法
|
TW200918089A
(en)
|
2007-07-16 |
2009-05-01 |
Genentech Inc |
Humanized anti-CD79b antibodies and immunoconjugates and methods of use
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
JP6126773B2
(ja)
|
2007-09-04 |
2017-05-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原(psca)抗体
|
EP2209498A2
(de)
*
|
2007-10-03 |
2010-07-28 |
Cornell University |
Behandlung von proliferativen erkrankungen mit psma-antikörpern
|
NZ585556A
(en)
|
2007-11-07 |
2012-07-27 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
|
KR20100097691A
(ko)
|
2007-11-12 |
2010-09-03 |
테라클론 사이언시스, 아이엔씨. |
인플루엔자의 치료 및 진단을 위한 조성물 및 방법
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
SI2657253T1
(sl)
|
2008-01-31 |
2017-10-30 |
Genentech, Inc. |
Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
AU2009223688B2
(en)
|
2008-03-10 |
2014-12-11 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
|
ES2368700T3
(es)
|
2008-04-11 |
2011-11-21 |
Emergent Product Development Seattle, Llc |
Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
JP5986745B2
(ja)
|
2008-07-15 |
2016-09-06 |
アカデミア シニカAcademia Sinica |
Ptfe様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
|
US20100069616A1
(en)
*
|
2008-08-06 |
2010-03-18 |
The Regents Of The University Of California |
Engineered antibody-nanoparticle conjugates
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
EP2727606A3
(de)
|
2008-09-08 |
2015-09-23 |
Psma Development Company, L.L.C. |
Verbindungen zur tötung von psma-expriemierenden und taxane-resistenten krebszellen
|
WO2010062857A1
(en)
|
2008-11-26 |
2010-06-03 |
Allergan, Inc. |
Klk-13 antibody inhibitor for treating dry eye
|
RU2636046C2
(ru)
|
2009-01-12 |
2017-11-17 |
Сайтомкс Терапьютикс, Инк |
Композиции модифицированных антител, способы их получения и применения
|
WO2010096486A1
(en)
*
|
2009-02-17 |
2010-08-26 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
BRPI1011384A2
(pt)
|
2009-02-23 |
2016-03-15 |
Cytomx Therapeutics Inc |
pro-proteinas e seus metodos de uso
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
ES2572728T3
(es)
|
2009-03-20 |
2016-06-02 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HER biespecíficos
|
AU2010236787A1
(en)
|
2009-04-01 |
2011-11-10 |
Genentech, Inc. |
Anti-FcRH5 antibodies and immunoconjugates and methods of use
|
CA2759506A1
(en)
|
2009-04-23 |
2010-10-28 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
AU2010249787A1
(en)
|
2009-05-20 |
2011-12-22 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
JP5705836B2
(ja)
|
2009-05-29 |
2015-04-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター
|
EP2448966B1
(de)
|
2009-07-03 |
2018-11-14 |
Avipep Pty Ltd |
Immunkonjugate und verfahren zu ihrer herstellung
|
US20110038871A1
(en)
|
2009-08-11 |
2011-02-17 |
Veena Viswanth |
Ccr2 inhibitors for treating conditions of the eye
|
BR112012009409A2
(pt)
|
2009-10-22 |
2017-02-21 |
Genentech Inc |
método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
|
AR079217A1
(es)
|
2009-11-30 |
2012-01-04 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
CA2782333C
(en)
|
2009-12-02 |
2019-06-04 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
EP2507381A4
(de)
|
2009-12-04 |
2016-07-20 |
Hoffmann La Roche |
Multispezifische antikörper, antikörperanaloge, zusammensetzungen und verfahren
|
SG181563A1
(en)
|
2009-12-08 |
2012-07-30 |
Abbott Gmbh & Co Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
CA2784610C
(en)
|
2009-12-23 |
2020-07-14 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
US8900588B2
(en)
*
|
2010-01-08 |
2014-12-02 |
Les Laboratories Servier |
Methods for treating breast cancer
|
JP5981853B2
(ja)
|
2010-02-18 |
2016-08-31 |
ジェネンテック, インコーポレイテッド |
ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
|
MX2012009215A
(es)
|
2010-02-23 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
US9631018B2
(en)
|
2010-03-26 |
2017-04-25 |
The Trustees Of Dartmouth College |
Vista regulatory T cell mediator protein, vista binding agents and use thereof
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
EP2566510A1
(de)
|
2010-05-03 |
2013-03-13 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und verfahren zur reduzierung der viskosität von proteinhaltigen formulierungen
|
MA34291B1
(fr)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
CA2835489C
(en)
|
2010-05-10 |
2018-03-06 |
Chi-Huey Wong |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
PT2580240T
(pt)
|
2010-06-14 |
2019-03-29 |
Lykera Biomed S A |
Anticorpos as100a4 e utilizações terapêuticas dos mesmos
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
JP2013540701A
(ja)
|
2010-08-12 |
2013-11-07 |
セラクローン サイエンシーズ, インコーポレイテッド |
抗赤血球凝集素抗体組成物およびその使用方法
|
PT3556396T
(pt)
|
2010-08-31 |
2022-07-04 |
Scripps Research Inst |
Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
US20130224116A1
(en)
|
2010-11-05 |
2013-08-29 |
TransBio Ltd. |
Markers of Endothelial Progenitor Cells and Uses Thereof
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
EP2465536A1
(de)
*
|
2010-12-14 |
2012-06-20 |
CSL Behring AG |
CD89-Aktivierung in Therapie
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
AU2012217867A1
(en)
|
2011-02-14 |
2013-09-05 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
EP2685968A1
(de)
|
2011-03-15 |
2014-01-22 |
Theraclone Sciences, Inc. |
Zusammensetzungen und verfahren zur therapie und diagnose von grippe
|
EP2699598B1
(de)
|
2011-04-19 |
2019-03-06 |
Pfizer Inc |
Kombinationen aus anti-4-1bb-antikörpern und adcc-induzierenden antikörpern zur behandlung von krebs
|
WO2012142662A1
(en)
|
2011-04-21 |
2012-10-26 |
Garvan Institute Of Medical Research |
Modified variable domain molecules and methods for producing and using them b
|
WO2012158948A1
(en)
|
2011-05-17 |
2012-11-22 |
The Rockefeller University |
Human immunodeficiency virus neutralizing antibodies adn methods of use thereof
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
WO2013063229A1
(en)
|
2011-10-25 |
2013-05-02 |
The Regents Of The University Of Michigan |
Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
|
CA2857114A1
(en)
|
2011-11-30 |
2013-06-06 |
Genentech, Inc. |
Erbb3 mutations in cancer
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
CA2855570A1
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
US10118958B2
(en)
|
2011-12-14 |
2018-11-06 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
MY176695A
(en)
|
2012-01-27 |
2020-08-19 |
Abbvie Inc |
Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
|
RU2627185C1
(ru)
*
|
2012-03-16 |
2017-08-03 |
Коваген Аг |
Новые связывающие молекулы с противоопухолевой активностью
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック, インコーポレイテッド |
Her3阻害剤に関する診断及び治療
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
WO2013169693A1
(en)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
JP6267689B2
(ja)
|
2012-05-10 |
2018-01-24 |
バイオアトラ、エルエルシー |
多重特異性モノクローナル抗体
|
WO2014039983A1
(en)
|
2012-09-07 |
2014-03-13 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
AU2013306098A1
(en)
|
2012-08-18 |
2015-02-12 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
WO2014031762A1
(en)
|
2012-08-21 |
2014-02-27 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
PL2908912T3
(pl)
|
2012-10-18 |
2021-05-17 |
The Rockefeller University |
Szeroko neutralizujące przeciwciała anty-hiv
|
MX363188B
(es)
|
2012-11-30 |
2019-03-13 |
Hoffmann La Roche |
Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
ES2753419T3
(es)
|
2013-06-07 |
2020-04-08 |
Univ Duke |
Inhibidores del factor H del complemento
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
EP3013347B1
(de)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glykankonjugate und verwendung davon
|
CN105682666B
(zh)
|
2013-09-06 |
2021-06-01 |
中央研究院 |
使用醣脂激活人类iNKT细胞
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
PL3712174T3
(pl)
|
2013-12-24 |
2022-07-04 |
Janssen Pharmaceutica Nv |
Przeciwciała i fragmenty anty-vista
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
WO2015108719A1
(en)
|
2014-01-14 |
2015-07-23 |
The Medical College Of Wisconsin, Inc. |
Targeting clptm1l for treatment and prevention of cancer
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US9982041B2
(en)
|
2014-01-16 |
2018-05-29 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
TWI687428B
(zh)
|
2014-03-27 |
2020-03-11 |
中央研究院 |
反應性標記化合物及其用途
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
CN106573971A
(zh)
|
2014-05-27 |
2017-04-19 |
中央研究院 |
抗cd20醣抗体及其用途
|
EP3149161B1
(de)
|
2014-05-27 |
2021-07-28 |
Academia Sinica |
Fucosidase aus bacteroiden und verfahren damit
|
AU2015267045B2
(en)
|
2014-05-27 |
2021-02-25 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
CN113549153A
(zh)
|
2014-05-29 |
2021-10-26 |
宏观基因有限公司 |
三特异性结合分子和其使用方法
|
EA037006B1
(ru)
|
2014-06-06 |
2021-01-26 |
Бристол-Майерс Сквибб Компани |
Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
|
MX2016016310A
(es)
|
2014-06-11 |
2017-10-20 |
A Green Kathy |
Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
WO2016040369A2
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
NZ730348A
(en)
|
2014-09-26 |
2024-03-22 |
Macrogenics Inc |
Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CA2961439A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
RS60631B1
(sr)
|
2014-11-21 |
2020-09-30 |
Bristol Myers Squibb Co |
Antitela protiv cd73 i njihova upotreba
|
EP3227341A1
(de)
|
2014-12-02 |
2017-10-11 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Anti-mutante calreticulin-antikörper und deren verwendung bei der diagnose und therapie von myeloiden malignomen
|
EP3226900A4
(de)
|
2014-12-05 |
2018-09-19 |
Immunext, Inc. |
Identifizierung von vsig8 als vermeintlicher vista-rezeptor und dessen verwendung zur herstellung von vista/vsig8-modulatoren
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
TWI708786B
(zh)
|
2014-12-23 |
2020-11-01 |
美商必治妥美雅史谷比公司 |
針對tigit之抗體
|
PT3240801T
(pt)
|
2014-12-31 |
2021-02-18 |
Checkmate Pharmaceuticals Inc |
Imunoterapia antitumoral combinada
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
EP3248005B1
(de)
|
2015-01-24 |
2020-12-09 |
Academia Sinica |
Neuartige glycankonjugate und verfahren zur verwendung davon
|
AU2015380455A1
(en)
|
2015-01-26 |
2017-08-03 |
Macrogenics, Inc. |
Multivalent molecules comprising DR5-binding domains
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CN107580500B
(zh)
|
2015-02-19 |
2023-05-30 |
康姆普根有限公司 |
抗pvrig抗体和使用方法
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CA2987410A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
JP7026509B2
(ja)
|
2015-06-24 |
2022-02-28 |
ヤンセン ファーマシューティカ エヌブイ |
抗vista抗体およびフラグメント
|
AU2016285920A1
(en)
|
2015-06-29 |
2018-02-01 |
Bristol-Myers Squibb Company |
Antibodies to CD40 with enhanced agonist activity
|
KR20180034588A
(ko)
|
2015-07-30 |
2018-04-04 |
마크로제닉스, 인크. |
Pd-1-결합 분자 및 그것의 사용 방법
|
NZ739721A
(en)
|
2015-08-07 |
2019-09-27 |
Imaginab Inc |
Antigen binding constructs to target molecules
|
EP3352760A4
(de)
|
2015-09-21 |
2019-03-06 |
Aptevo Research and Development LLC |
Cd3-bindende polypeptide
|
RU2638457C2
(ru)
|
2015-09-28 |
2017-12-13 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
|
WO2017062619A2
(en)
|
2015-10-08 |
2017-04-13 |
Macrogenics, Inc. |
Combination therapy for the treatment of cancer
|
US10745382B2
(en)
|
2015-10-15 |
2020-08-18 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
JP6998869B2
(ja)
|
2015-11-08 |
2022-02-04 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体のスクリーニング方法
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
CR20180318A
(es)
|
2015-12-14 |
2018-09-19 |
Macrogenics Inc |
Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
|
CN116920085A
(zh)
|
2016-02-12 |
2023-10-24 |
詹森药业有限公司 |
抗-vista(b7h5)抗体
|
UY37127A
(es)
|
2016-02-17 |
2017-08-31 |
Macrogenics Inc |
Moléculas de unión a ror1, y métodos de uso de las mismas
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
EA201891983A8
(ru)
|
2016-03-04 |
2020-05-28 |
Бристол-Майерс Сквибб Компани |
Комбинированная терапия антителами к cd73
|
SG11201807677YA
(en)
|
2016-03-04 |
2018-10-30 |
Univ Rockefeller |
Antibodies to cd40 with enhanced agonist activity
|
TW201808978A
(zh)
|
2016-03-08 |
2018-03-16 |
中央研究院 |
N-聚醣及其陣列之模組化合成方法
|
WO2017165681A1
(en)
|
2016-03-24 |
2017-09-28 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
RU2021111187A
(ru)
|
2016-04-15 |
2021-04-29 |
Янссен Фармасьютикалз, Инк. |
Антитела против человеческого vista и их применение
|
MY198114A
(en)
|
2016-04-15 |
2023-08-04 |
Macrogenics Inc |
Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
|
MA44723A
(fr)
|
2016-04-18 |
2019-02-27 |
Celldex Therapeutics Inc |
Anticorps agonistes se liant au cd40 humain et leurs utilisations
|
EP3454863A1
(de)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombinationstherapien zur behandlung von krebs
|
CA3029991A1
(en)
|
2016-07-08 |
2018-01-11 |
Bristol-Myers Squibb Company |
1,3-dihydroxy-phenyl derivatives useful as immunomodulators
|
JP7027401B2
(ja)
|
2016-07-14 |
2022-03-01 |
ブリストル-マイヤーズ スクイブ カンパニー |
Tim3に対する抗体およびその使用
|
JP7213549B2
(ja)
|
2016-08-22 |
2023-01-27 |
シーエイチオー ファーマ インコーポレイテッド |
抗体、結合性断片、および使用の方法
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
JP7083819B2
(ja)
*
|
2016-09-30 |
2022-06-13 |
セントレ ナショナル デ ラ レセルシュ シャンティフィク |
細胞マーカー
|
EP3519824A1
(de)
|
2016-10-03 |
2019-08-07 |
Abbott Laboratories |
Verbesserte verfahren zur beurteilung des uch-l1-status in patientenproben
|
CN110267971B
(zh)
|
2016-11-07 |
2023-12-19 |
百时美施贵宝公司 |
免疫调节剂
|
JP7106572B2
(ja)
|
2016-12-20 |
2022-07-26 |
ブリストル-マイヤーズ スクイブ カンパニー |
免疫調節剤として有用な化合物
|
EP3558368A4
(de)
|
2016-12-23 |
2020-12-30 |
MacroGenics, Inc. |
Adam9-bindende moleküle und verfahren zur verwendung davon
|
EP3565839A4
(de)
|
2017-01-05 |
2021-04-21 |
Gensun Biopharma Inc. |
Checkpoint-regulatorantagonisten
|
EP3565845A4
(de)
|
2017-01-06 |
2020-10-07 |
Biosion, Inc. |
Erbb2-antikörper und deren verwendungen
|
US11377497B2
(en)
|
2017-01-23 |
2022-07-05 |
Suzhou Alphamab Co., Ltd. |
PD-L1 binding polypeptide or composite
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
US11016092B2
(en)
|
2017-03-23 |
2021-05-25 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
|
ES2961550T3
(es)
|
2017-03-27 |
2024-03-12 |
Bristol Myers Squibb Co |
Derivados de isoquinolina sustituidos como inmunomoduladores
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
US10877048B2
(en)
|
2017-04-15 |
2020-12-29 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
EP3615569A1
(de)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
|
US10877038B2
(en)
|
2017-04-28 |
2020-12-29 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
AU2018272054A1
(en)
|
2017-05-25 |
2019-09-26 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
JP7269183B2
(ja)
|
2017-05-30 |
2023-05-08 |
アボット・ラボラトリーズ |
心臓トロポニンiを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
|
KR20200020858A
(ko)
|
2017-06-23 |
2020-02-26 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-1의 길항제로서 작용하는 면역조정제
|
WO2019010131A1
(en)
|
2017-07-03 |
2019-01-10 |
Abbott Laboratories |
IMPROVED METHODS FOR MEASURING CARBOXY TERMINATION HYDROLASE LEVELS OF UBIQUITIN L1 IN BLOOD
|
CN111094334A
(zh)
|
2017-07-19 |
2020-05-01 |
美国卫生与公众服务部 |
用于诊断和治疗乙肝病毒感染的抗体和方法
|
US11492375B2
(en)
|
2017-10-03 |
2022-11-08 |
Bristol-Myers Squibb Company |
Cyclic peptide immunomodulators
|
WO2019089921A1
(en)
|
2017-11-01 |
2019-05-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
BR112020010085A2
(pt)
|
2017-12-09 |
2020-10-13 |
Abbott Laboratories |
métodos para auxiliar no diagnóstico e avaliar uma lesão cerebral traumática em um indivíduo humano usando uma combinação de gfap e uch-l1
|
US11022617B2
(en)
|
2017-12-09 |
2021-06-01 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
|
RU2020122822A
(ru)
|
2017-12-12 |
2022-01-13 |
Макродженикс, Инк. |
Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний
|
CR20200313A
(es)
|
2017-12-19 |
2020-12-01 |
Univ Rockefeller |
VARIANTES DE DOMINIO DE Fc DE IgG HUMANA CON FUNCIÓN EFECTIVA MEJORADA
|
EP3732198A1
(de)
|
2017-12-27 |
2020-11-04 |
Bristol-Myers Squibb Company |
Anti-cd40-antikörper und verwendungen davon
|
JP7358361B2
(ja)
|
2018-01-12 |
2023-10-10 |
ブリストル-マイヤーズ スクイブ カンパニー |
Tim3に対する抗体およびその使用
|
US11414418B2
(en)
|
2018-01-23 |
2022-08-16 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
US11685781B2
(en)
|
2018-02-15 |
2023-06-27 |
Macrogenics, Inc. |
Variant CD3-binding domains and their use in combination therapies for the treatment of disease
|
WO2019169123A1
(en)
|
2018-03-01 |
2019-09-06 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
TW202003565A
(zh)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
抗mica及/或micb抗體及其用途
|
EA202092316A1
(ru)
|
2018-03-28 |
2021-05-25 |
Бристол-Маерс Сквибб Компани |
Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
|
CA3096674A1
(en)
|
2018-04-12 |
2019-10-17 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
WO2019213416A1
(en)
|
2018-05-02 |
2019-11-07 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
EP3569618A1
(de)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonisierender cd73-antikörper
|
WO2020006511A1
(en)
|
2018-06-29 |
2020-01-02 |
Gensun Biopharma, Inc. |
Trispecific antagonists
|
US20200109200A1
(en)
|
2018-10-09 |
2020-04-09 |
Genentech, Inc. |
Methods and systems for determining synapse formation
|
PE20211284A1
(es)
|
2018-11-16 |
2021-07-19 |
Bristol Myers Squibb Co |
Anticuerpos anti-nkg2a y usos de los mismos
|
WO2020115223A1
(en)
|
2018-12-05 |
2020-06-11 |
Katholieke Universiteit Leuven |
S100a4 as a marker of treatment with spironolactone, pioglitazone and metformin
|
CN109929037B
(zh)
|
2019-04-01 |
2023-03-17 |
华博生物医药技术(上海)有限公司 |
针对程序性死亡配体的结合物及其应用
|
US10851157B2
(en)
|
2019-07-01 |
2020-12-01 |
Gensun Biopharma, Inc. |
Antagonists targeting the TGF-β pathway
|
JP2022541652A
(ja)
|
2019-07-26 |
2022-09-26 |
ヴァンダービルト ユニバーシティ |
エンテロウイルスd68に対するヒトモノクローナル抗体
|
US20240124417A1
(en)
|
2019-10-04 |
2024-04-18 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
IL295310A
(en)
|
2020-02-11 |
2022-10-01 |
Univ Vanderbilt |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
|
US20230140384A1
(en)
|
2020-03-09 |
2023-05-04 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
PL4045533T3
(pl)
|
2020-03-26 |
2024-04-15 |
Vanderbilt University |
Ludzkie przeciwciała monoklonalne przeciwko ciężkiemu ostremu zespołowi oddechowemu wywołanemu koronawirusem 2 (sars-cov-2)
|
WO2021211331A1
(en)
|
2020-04-13 |
2021-10-21 |
Abbott Point Of Care Inc. |
METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
EP4175650A1
(de)
|
2020-07-06 |
2023-05-10 |
Kiromic BioPharma, Inc. |
Mesothelinisoformbindende moleküle und chimäre pd1-rezeptormoleküle, zellen damit und verwendungen davon
|
US20220043000A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Methods and kits for detecting sars-cov-2 protein in a sample
|
US20220043003A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Rapid Diagnostics International Unlimited Company |
Assays for detecting sars-cov-2
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
US20230399407A1
(en)
*
|
2020-11-06 |
2023-12-14 |
Korea University Research And Business Foundation |
Fc alpha receptor binding antibody
|
WO2022108627A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的hla展示肽
|
EP4314068A1
(de)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antikörper gegen gespaltenes cdcp1 und verwendungen davon
|
KR20240004801A
(ko)
|
2021-05-05 |
2024-01-11 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조절제로서 유용한 락톤 및 락탐 함유 화합물
|
AU2022279156A1
(en)
|
2021-05-18 |
2023-11-02 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
EP4352077A1
(de)
|
2021-06-09 |
2024-04-17 |
Bristol-Myers Squibb Company |
Zyklische peptidimmunmodulatoren
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
WO2023283523A1
(en)
|
2021-07-06 |
2023-01-12 |
Bristol-Myers Squibb Company |
2,3-dihydrobenzo[b][l,4]dioxin-6-yl containing compounds useful as immunomodulators
|
WO2023034777A1
(en)
|
2021-08-31 |
2023-03-09 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
AU2022354059A1
(en)
|
2021-09-30 |
2024-03-28 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023089131A1
(en)
|
2021-11-19 |
2023-05-25 |
Lykera Biomed, S.A. |
Treatment and diagnosis of diseases associated to pathogenic fibrosis
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|